Senedi Propietary Manufacturer	Atecolizumab Transisia Generateda	Avelumab Evento Plant	Durvalumab Indias	Cemiplimab-owls Ultayo	Nivolumab Optive	Pembrolizumab Reyloula	Dostarlimab-gab Jengedi GSK	lpilimumat Terray
Manufacturer	Commissão							
reficitions			2019277712		100	Mesk	GIK	IMS
					DOSE			
Unothelial  Weststo, or locally advanced thothelial CA in  registers ineligible patients and whose furners.  Repress PD-12	SSDing 42 weeks, or 1200ing 45 weeks, or 1800ing 46 weeks (PD- L1 classed benon- sofitosing instance cetts (IC) covering >= 15 of the busing 2010)					200mg qlf weeks or 600mg qlf weeks (PD- 51 expression: CPS >= 30 by PDR-approved 5e(5)		
MELETIC of Iscally abanced Dothers CA in platinum-containing chemitherapy meligible patients regardless of PD-L1 classic	BSDing q2 weeks, 1200ing q6 weeks, or 1880ing q6 weeks	Marie Consider	-		240mg q2 weeks or 680mg adventeds	200mg qil weeks or 000mg qil weeks 200mg qil weeks or 000ms oli weeks		
Metastatic wodheltal cardinoma, Orlocally advanced, with progression during or after platerium-cardinomy the mother days or within 13 morths of nesadjuvant, or adjuvant Tolkoment with platerium-containing the mother days.			withdraw 1/21/21		45weeks	dating of weeks		
Metactatic underhal carcinoma, Or locally advanced, find time maintenance is patient; with no progression following find-line platinum-containing themsifiecture:		800mg q2 weeks						
Metastatic or locally advanced Unothertal CA/ 2nd line	withdraw (A)/71				240mgq3week. No ted	200mg që weeks 200mg që weeks		
Ballius Calmette-Guerin (BCO) wine sporous, high- top, not emission involve Babler Ch (BMRIC) with nannonna in other of my lap politic tumors who are ineligible for or have elected not to-undergia yide clarity.						200ng qil weeks or 000ng qil weeks		
RCC		300mg q2 weeks +				200mg qit weeks or 600mg qit weeks + Janionib		
texal sell cardinoma, Advanced, first line treatment or combination with authoria femal sell cardinoma, Advanced, first-line treatment or combination with calcimetants					240mg q2 weeks or 480mg	settinds		
is combination with calconnetamb behaviord renal Cell CA after prior antiangragenic therapy					adwerks 200 ng q2 weeks or 680 ng adwerks			
therapy intermediate or poor risk, previously untreated advanced RCC in combination with spilumiumab					at works Ing/kg fallowed by spitmumab Ing/kg on the same day q1 weeks x d doses, then 200mg q2 weeks or 200mg q4 weeks			Singfug following envolumeds Singfug of came day, qif weeks doore. Then admini envolumed as cingfe
NSCLC								
Mediatric NYCLE first line, movietherapy	SDing (Dweeks, 1300ing (Dweeks, 1300ing (Dweeks, 1400ing (Dweeks) (DF1) expression > 50% or FD-11 (Date-of-tuner (Conversing IC conversing IC conversing IC conversing IC conversing IC conversion (Dweeks) and part or AKK greams: tumor abertations					200mg qil weeks (FD- 600mg qil weeks (FD- 6.1 expression >= 2%)		
Itage III NICLC where potients are not conditates for ourgoninesection or definitive the monadiation, ourgle agent, first line						200mg qt weeks ar d20mg qt weeks (FD L1 expression >= 2%)		
Non-unail oril lung canon, metactatic or leasily advanced disease metigate for surgical resection or definitive chemicalization, first line, with no TOPK,				Strang for qit weeks (TPS>+50%)				
National constitution for small cell lang cancer, More statements on statements on understated with interchanding, politically, and CMRSSQUESTED inspection with the TOPR or XXX generates families interchanding statements.	1205ng qlf weeks(w) or w/o beaucountable. Administer plos to chemistherapy and beaucountable. Tallowing completion of e-4-cycles of chemistherapy, and if beaucountable. Seaucountable, may give truncing 825ng give truncing 825ng queeks, cr 2685ng qlf weeks, or 2685ng qlf							
Numerous non-result cell long cancer, MARKERED, filed line I Vestines to combination with the committee of the committee of the committee of patients, with no EDPS or ASS genoms; fumor laberations	1200ing ell weeks, given prior to chemical programme of chemical programme of discourse of chemic may give tocombing 800ing q2 weeks, 1200ing q1 weeks, or 1880ing q4 weeks, or 1880ing q4 weeks.							
Non-small oil bangcance, AMSACIDIC, with progression during or after platinum-based themside-opy, patients with AEE or BOM genomic barror abertations thould have disease progression in PER-opproved the Opy for these abertations	Mest. BIDING QZweeks, IJDDING qEweeks, or IJDDING qEweeks				360mgq3 weeks or 660mg qCweeks	200mg qt weeks or 600mg qt weeks (PD 51 expression >=0%)		
Non-unall oil lung cancer, toweredable Mage III, without progression following consument platmum- based chemotherapy and radiation therapy			Sting/lig q Sweeks or 1900ing q Sweeks (max 12 months)					
Metastatic NSCLC expressing PD-L1 (>=26) with no BEPE or ACK genomic tumor abentations, first-line presonent in combination with ipitumumab					Sing/ng q2 weeks with quinnumab 2 mg/ng q6 weeks for up to 2 years			Singing 42 weeks to sprimumate Singing weeks for up to 2 y
brachment in combination with lightuniumab Metaletatic of recurrent hitcs: L with na BDPR of ALK, genamic furmor abendations as first fine brachment, in combination with lightuniumab and 2 system of platinium-doubles the motherapy.					brighlig q2 weeks with spinnumab brighlig q5 weeks for up to 2 years bibrig q3 weeks w/ spinnumab brighlig q6 weeks and 2 cycles of platnum challer shematherapy			Img/sg q2 weeks w sprimumab Img/sg weeks for up to 2 yr 360mg q5 weeks w sprimmumab Img/s weeks and 2 cycles platform—doubles shemotheraby
platinum-doublet the motherapy Metastatic nanoquamous NSCLC, first-line, in combination with genietineed and platinum themsitted pay, with no SSPE or NSC genomic tumor th acceptance.						200mg që weeks or 000mg që weeks		
Metastatic squamous NSCUC, fixth line, is combination w/carboylatin and either pacitizatel or						200mg of weeks or 200mg of weeks		
Melanoma								
onesectable or metactatic melanoma, monotherapy					24Drng q/Jweeks or 68Drng q6 weeks	200mg of weeks or 200mg of weeks		hng/kgqlueekx 0
Dissoctable or metastatic metasoma, dual the opy  Welanons with lymph node inschement. Adjurant					Singlig with IPI qibek e d.> 200mg qJ weeks or 680mg edwerks 200mg qJweeks or 680mg qd weeks	200mg qbweeks or d30mg qb weeks		10 vo 3 mg/kg + 171 2 q 8 uk x 6 > 10 vo 680 uc r65 20 mg/kg q 8 uc r6s.
Military reference where Table or any Table	Ming stweets in				weeks	dating of weeks		weeks 20ng/kg q2 weeks doors, followed by 20ng/kg q 12 week to tunker
Milliguest melasions, unero-catélier erecutatio, 869 900 millione, pictive, accidentismos veta planetos à and vensualifers :	Bibling 47 weeks in combination with obbinetimb + weemurafemib. Prior to initiation of tecentring patients chould receive a 28-day technology of cobmetimb + weemurafemib.							
Soutemous cell H&N Recurrent or metadatic opulmous cell head and leck CA with disease progression on or after a			<u> </u>		24Drog q2 weeks or 64Drog q0 weeks	200mg q5 weeks or 000mg q6 weeks		
neds CA with disease progression on or after a elatinum based therapy Metastatic or unresectable, recurrent MMSCC, fina- tine, in combination with platinum and PU					qCweeks	dating of weeks or dating of weeks or		
ine, is combination with platinum and PD Metastatic or unresectable, current MMCC, final- ine, origin agent						000mg of weeks or 000mg of weeks or 000mg of weeks (PD L1 expression >=0)		
CHL Hodgkin hymphoma that hac relapsed or progressed					240mg-q2 weeks or 640mg q-Sweeks	LI expression >=0)		
offer auto-16CT and brentummak vedution  nodgian hymphomia that hat reliaped or progressed  other for more brent of systemic therapy that  missless auto-16CT  terkinolory out, that has reliaped after 8 or more prior  nos of therapy.					qCweeks 28Drig qZ weeks or 68Drig qCweeks			
includes auto-MSCT telractory ons that has relapsed after 1 or more prior trees of thessay						200mg qt weeks or 000mg op weeks		
PMISCL teliacory Minary Medactival Lage III-cell symphoma, or who have relayed after 2 or more soor times of therape						200mg of weeks or 000mg of weeks		
MS-h or dMMR talld tumor, unrecedible or metactable, 2-8, Mo- m/MMI in patients with no acceptable						200mg që weeks or 000mg që weeks		
Colonectal  Description of the second of the						Money of a		
ammentation of metabolic MSH or or different cert, five the comment cancer that has been added an experience cancer that has been appreciated cancer that has been appreciated for the control of the commentation of the control of th					Accomple agent: 280mg q2 merks or 800mg q4 weeks, or combination. Nogling Solomed by priminantal Engling corche came day q3 weeks x 6 doors, then 280mg q2 weeks or 680mg q4 weeks.	200mg qil weeks or 200mg qil weeks or 200mg qil weeks or 200mg qil weeks		IPI Sing/kg follows: Sing/kg in the cam glf weeks x disses single agent